肿瘤坏死因子治疗肺癌恶性胸水的疗效观察

Curative Efficacy of Recombinant Mutant Human Tumor Necrosis Factor for Malignant Pleural Effusions in Patients with Lung Cancer

目的评价顺铂±重组改构人肿瘤坏死因子(rmhTNF)治疗恶性胸腔积液(MPE)的疗效及毒副反应。方法对54例晚期非小细胞肺癌并发恶性胸腔积液患者的治疗进行回顾性分析,A组为单用顺铂治疗组,B组为顺铂联合rmhTNF治疗组,比较两组疗效。结果 A组31例,总有效率(CR+PR)为58.06%。B组23例,总有效率(CR+PR)为86.96%。B组的总有效率高于A组,两者之间的差别具有统计学意义(χ2=5.286,P=0.021)。结论 rmhTNF与顺铂具有协同作用,两药联合胸腔内注射可以作为非小细胞肺癌合并恶性胸腔积液患者的理想治疗方案,其疗效优于单用顺铂。

Objective To evaluate the efficacy and side effects of cisplatin with recombinant mutant human tumor necrosis factor（rmhTNF）for malignant pleural effusions（MPE）.Methods The clinical data of 54 patients with non-small cell lung cancer complicated with MPE were analyzed retrospectively.Group A were treated by cisplatin,and group B were by combination therapy with rmhTNF and cisplatin.The curative effects were compared.Results The total effective rate（CR＋PR）of group A of 31 cases was 58.06%,the total effective rate（CR＋PR）of group B of 23 cases was 86.96%.The total effective rate of group B was higher than that of group A,the difference between the two was statistically significant（χ2=5.286,P=0.021）.Conclusion The recombinant modified human tumor necrosis factor（rmhTNF）and cisplatin have a synergistic effect,so the combination therapy can be used as an optimal treatment for patients with non-small cell lung cancer complicated with MPE,and its efficacy is superior to cisplatin alone.